Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | RELA | Q04206 | 2/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CHAT | P28329 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5633115 | 1.00 | CYP2C19 (0.44) | CYP2C19RELAGRM5NPC1L3MBTL1 | |
| SCHEMBL2789093 | 0.78 | CYP2C19 (0.48) | CYP2C19RELANPC1L3MBTL1MAOB | |
| SCHEMBL6281994 | 0.78 | CYP2C19 (0.48) | CYP2C19RELANPC1L3MBTL1MAOB | |
| SCHEMBL2785212 | 0.76 | CYP2C19 (0.47) | CYP2C19RELANPC1L3MBTL1MAOB | |
| SCHEMBL11093287 | 0.74 | CYP2C19 (0.46) | CYP2C19RELANPC1L3MBTL1MAOB | |
| SCHEMBL2744182 | 0.74 | CYP2C19 (0.48) | CYP2C19RELAGRM5NPC1L3MBTL1 | |
| SCHEMBL2744188 | 0.74 | CYP2C19 (0.48) | CYP2C19RELAGRM5NPC1L3MBTL1 | |
| SCHEMBL28047534 | 0.73 | CYP2C19 (0.49) | CYP2C19RELANPC1L3MBTL1MAOB | |
| SCHEMBL6286942 | 0.72 | CYP2C19 (0.55) | CYP2C19RELAMAOBEGFRCHAT | |
| SCHEMBL28939716 | 0.72 | CYP2C19 (0.55) | CYP2C19RELAMAOBEGFRCHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288566-B2 | N-hydroxyformamidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-30 | — | — | US | disclosed |
| US-20060004078-A1 | N-hydroxyformamidine derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004078-A1 | N-hydroxyformamidine derivatives | FLT4, FLT1, PGF | CYP2C19 52/4885RELA 1342/4885GRM5 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.